Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

(Dana-Farber Cancer Institute) Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial in these patients of one such agent -- nivolumab -- indicate that along with signs of effectiveness, it also produced significant side effects at the dose initially studied. The findings indicate a need for further clinical trials in this group...